Divine Aleru, Microbiome Signatures Research Coordinator

This study examines the association between metformin use and survival outcomes in ovarian cancer patients. A significant survival benefit was found in diabetic patients, suggesting metformin may improve ovarian cancer prognosis, although further research is needed for non-diabetic patients.

This review explores the potential of repurposing non-oncological drugs for cancer therapy, highlighting their efficacy in preclinical studies and their mechanisms of action. It emphasizes the benefits of using established drugs to overcome cancer treatment challenges, particularly in overcoming drug resistance and reducing costs.

The review explores the potential of repurposing non-oncological drugs for ovarian cancer treatment, highlighting their ability to improve chemotherapy effectiveness and reduce treatment costs, with promising findings from preclinical studies and clinical trials.

The study explores drug repositioning as a transformative strategy for ovarian cancer (OC) treatment, highlighting the potential of repurposing existing drugs for more effective, accelerated, and cost-efficient therapies. The review focuses on in vitro experiments with various cancer cell lines and preclinical in vivo models to evaluate the efficacy of repurposed drugs, […]

This review explores the role of targeted therapies in ovarian cancer treatment, focusing on the potential of angiogenesis inhibitors, PARP inhibitors, and folate receptor alpha inhibitors. While promising, further clinical trials and personalized approaches are necessary to enhance survival and treatment outcomes.

This review discusses the role of nutritional interventions in improving the nutritional status and clinical outcomes of women with ovarian cancer during treatment. It highlights the importance of personalized nutrition care and the need for more research to establish effective intervention strategies.

Bacterial vaginosis (BV) is caused by an imbalance in the vaginal microbiota, where the typically dominant Lactobacillus species are significantly reduced, leading to an overgrowth of anaerobic and facultative bacteria.

his systematic review highlights the role of metabolomics in ovarian cancer management, identifying key metabolic alterations in lipids and amino acids that could improve diagnosis, prognosis, and treatment strategies. Further validation is needed for clinical application.

This study profiles metabolic dysregulation in ovarian cancer, identifying key metabolites and pathways altered in OC tissues and biofluids. N1,N12-diacetylspermine emerges as a potential biomarker.

Mendelian randomization identified causal links between 9 metabolites and ovarian cancer risk. Some metabolites promote, others protect against OC. These findings suggest potential biomarkers for diagnosis and treatment but require clinical validation.

A two-sample MR of 486 metabolites reports suggestive causal links across OC and histotypes, maps caffeine/arginine/TCA and alpha-linolenic pathways, and surfaces microbially influenced xenobiotics as potential biomarkers; findings require replication before translation.

This review explores how heavy metals, including cadmium, lead, and mercury, contribute to the development of female cancers by mimicking estrogen, inducing oxidative stress, and causing DNA damage. These findings highlight the need for further research to understand the molecular mechanisms involved and develop effective prevention strategies.

This study investigates how sub-chronic exposure to lead, cadmium, and cobalt induces multidrug resistance in ovarian cancer cells, highlighting the role of drug efflux transporters and reduced apoptosis in treatment resistance. These findings underscore the importance of environmental metal exposure in cancer therapy effectiveness.

The study examines the association between urinary concentrations of heavy metals (arsenic, cadmium, mercury, lead) and survival in patients with advanced high-grade serous ovarian cancer. High levels of these metals correlate with worse outcomes, particularly lead, which significantly contributes to survival prognosis.

This study explores the role of lead and cadmium in gynecological malignancies, focusing on their ability to mimic estrogen and induce oxidative stress, contributing to cancer development. It highlights their potential as biomarkers for early detection and treatment.

This study explores how the concentration of heavy metals, particularly zinc and copper, in the blood of ovarian cancer patients correlates with their recurrence-free survival. It highlights the potential of these metals as biomarkers for prognosis and suggests environmental factors play a role in cancer outcomes.

This review explores the role of the microbiome in ovarian cancer, focusing on microbial dysbiosis and bacterial metabolites that influence inflammation and carcinogenesis. It highlights the potential of microbiome-based therapies, such as probiotics and antibiotics, to improve treatment outcomes and provide new diagnostic tools.

This review explores the ovarian cancer-associated microbiome’s role in shaping the inflammatory microenvironment of tumors. It discusses how microbial dysbiosis and its metabolites contribute to cancer progression, immune suppression, and therapeutic resistance, suggesting microbiome modulation as a potential therapeutic strategy.

This review explores how the microbiome influences ovarian cancer development, progression, and treatment response. It emphasizes microbial dysbiosis as a factor in carcinogenesis and offers insights into therapeutic opportunities like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review examines how the aging gut microbiome affects ovarian cancer progression. It highlights microbial dysbiosis as a common feature in both aging and cancer, with implications for novel therapeutic strategies like probiotics and fecal microbiota transplantation to improve treatment outcomes.

This review highlights the role of vaginal microbiota in ovarian cancer carcinogenesis, progression, and treatment. It discusses microbial dysbiosis and potential therapeutic interventions like probiotics and vaginal microbiota transplantation, offering promising avenues for improving cancer treatment.

This review highlights the significant role of the female reproductive tract microbiome in the development of gynecological cancers, focusing on microbial dysbiosis, estrogen regulation, and potential therapeutic strategies.

This review examines the role of the microbiome in gynecologic cancer development and treatment, emphasizing its potential for early diagnosis and therapeutic modulation. The microbiome’s influence on chemotherapy and immunotherapy responses offers new avenues for cancer management.

This review explores the role of the microbiome in ovarian cancer, emphasizing its potential for early diagnosis and treatment. The use of microbiome-based biomarkers and therapies like fecal and vaginal microbiome transplantation offers promising new avenues for cancer care.